Who is sponsoring NCT06660017?

NCT06660017 is sponsored by University of Oklahoma.

What condition does NCT06660017 study?

NCT06660017 studies Head and Neck Cancer.

What drugs are being tested in NCT06660017?

Interventions: Placebo, Ketamine Topical.

What is the status of NCT06660017?

NCT06660017 is currently NOT_YET_RECRUITING.

Last reviewed 2026-05-05 · How we verify

Ketamine Oral Rinse in the Management of Oral Mucositis in Head and Neck Cancer Patients Undergoing Radiation Therapy

NCT06660017 Phase 2 NOT_YET_RECRUITING

This 2-arm phase II study proposes to determine the efficacy of ketamine oral rinse in pain relief from mucositis in head and neck cancer patients undergoing radiation treatment.

Details

Lead sponsor	University of Oklahoma
Phase	Phase 2
Status	NOT_YET_RECRUITING
Enrolment	62
Start date	2026-06
Completion	2027-11

Conditions

Head and Neck Cancer

Interventions

Placebo
Ketamine Topical

Primary outcomes

Number of patients who have altered pain response from mucositis in head and neck cancer undergoing radiation treatment from using ketamine oral rinse. — 6 months
Review weekly questionnaires of patients who received ketamine oral rinse to assess if it helped with the pain of mucositis caused by the radiation in head and neck cancer patients.

Countries

United States